

The Resilience of Muscle Regenerative Capacity Following Volumetric Muscle Loss

Andrew Clark

Scientist, Contractor, Henry M. Jackson Foundation, Inc.

in support of

Extremity Trauma and Amputation Center of Excellence (EACE)
Assistant Professor, Uniformed Services University of the Health
Sciences





DISCLAIMER

The opinions or assertions contained herein are the private ones of the author/speaker and are not to be construed as official or reflecting the views of the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., the Department of Defense, the Uniformed Services University of the Health Sciences or any other agency of the U.S. Government. This work was prepared as part of official duties as U.S. Government employees and, therefore, is defined as U.S. Government work under Title 17 U.S.C. §101. Per Title 17 U.S.C. §105, copyright protection is not available for any work of the U.S. Government. Appearance of partner logo does not constitute or imply endorsement by the Department of Defense.


No Conflicts of interest

Volumetric Muscle Loss (VML)



Healthy



Injury



Scarring



↑ Fibrosis + ↓ Function = ↓ Quality of Life

¹Young-Woo Kim, Ho-Youn Park, Yoo-Joon Sur. Soft Tissue Reconstruction for Open Tibia Fractures. *Archives of Hand and Microsurgery*. 2020.

²Dziki, Jenna L.. "Extracellular matrix bioscaffolds for treatment of volumetric muscle loss." (2017).

Volumetric Muscle Loss

- Present in annual:
 - 150,000 open fractures
 - 30,000 gunshot wounds
 - 36,000 chainsaw accidents
 - 13,000 soft tissue sarcomas
- 77% of medically evacuated military personnel

Available Treatments


- Muscle Graft
- Muscle Transposition
- Rehabilitation



<https://www.oaepublish.com/articles/2347-9264.2022.89/image/fig1>


State of Preclinical Research

- Drugs
 - Little to no effect



State of Preclinical Research


- Scaffolds
 - Almost exclusively fibrose (turn into scar)
 - No new muscle growth without cell-based therapy
 - All muscle <0.2mm from defect border



Sicari BM, Agrawal V, Siu BF, Medberry CJ, Dearth CL, Turner NJ, Badylak SF. A murine model of volumetric muscle loss and a regenerative medicine approach for tissue replacement. *Tissue Eng Part A*. 2012 Oct;18(19-20):1941-8.

State of Preclinical Research

- Cells/tissue engineering
 - Some functional improvements
 - Integration, survivability, and regulatory issues
 - Scalability



https://cdmrp.health.mil/prorp/research_highlights/22Cullen_Das_highlight.aspx


?No new muscle formation

=

Muscle used up all its regenerative capacity?

Muscle the “highly regenerative tissue”


- Regrows perfectly after 80% death from:
 - Freeze injury
 - Mild blunt trauma
 - Toxins
 - 6 consecutive times



Hardy D, Besnard A, Latil M, Jouvion G, Briand D, Thépenier C, Pascal Q, Guguin A, Gayraud-Morel B, Cavaillon JM, Tajbakhsh S, Rocheteau P, Chrétien F. Comparative Study of Injury Models for Studying Muscle Regeneration in Mice. PLoS One. 2016 Jan 25;11(1):e0147198.


Muscle Stem Cells (Satellite Cells)

- Low in number
- Supposed to repopulate during activation
- 1 transplanted muscle stem cell can make ~50,000
- Depletion/senescence causes failure to regenerate/hypertrophy




Nguyen JH, Chung JD, Lynch GS and Ryall JG (2019) The Microenvironment Is a Critical Regulator of Muscle Stem Cell Activation and Proliferation. *Front. Cell Dev. Biol.* 7:254. doi: 10.3389/fcell.2019.00254

Muscle Injury Regeneration



<https://www.nature.com/articles/s41536-022-00204-z>

Hypertrophy (myonuclear accretion)



<https://journals.physiology.org/doi/10.1152/physrev.00039.2022>


“VML exceeds the muscles capacity to regenerate”

If true:




- 1) No muscle will regrow without cell transplant
- 2) Rehab limited to neurological-based strength gains
- 3) Future injuries won't recover at all

Injury Model

- Lewis Rat
- Tibialis Anterior muscle (lower limb)
- BaCl₂ injections
 - Causes myofiber necrosis (60%)
 - Fully recovers
- VML
 - 6 mm full thickness biopsy
 - 15% muscle mass





Functional Recovery




Muscle Fiber Histomorphometry


Histology cross-section site






Muscle Fiber Count




Muscle Fiber Size














PSR



Chronic VML + BaCl₂



Gene analysis – VML doesn't make much difference



Conclusion

- BaCl_2 + VML
 - No functional deficits over VML
 - No reduced muscle fiber # or size compared to VML
 - No increased fibrosis over VML

VML injured muscles still have a capacity to form large amounts of muscle!

Summary

- VML causes long term disability
- Limited clinical treatments, few in the pipeline
- VML retains the capacity to regrow large amounts of muscle tissue
 - Recover from secondary injury

THANKS!



Funding was provided by the Uniformed Services University of the Health Sciences (Award # HU00012320104)